Lupin Limited · NSE:LUPIN
Lupin — Q2 FY2021 Earnings Presentation
14 slides from Lupin's earnings presentation, Nov 5, 2020
Slide 1: Exchange filing cover letter for Q2 FY2021 Investor Presentation
November 5, 2020 BSE Limited Department of Corporate Services, P. J. Towers, Dalal Street, MUMBAI - 400 001. National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051. Dear Sir/Madam, Sub: Q2 FY2021 Investor Presentation. Pursuant to Regulation 3
Slide 2: Investor Presentation Q2 FY2021
Investor Presentation Q2 FY2021 November 05, 2020
Slide 3: Safe Harbor Statement
Safe Harbor Statement Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to diffe
Slide 4: Lupin – Awards and Accolades
Lupin – Awards and Accolades • Vinita Gupta named among Most Powerful Women in Business in India – #7 by Fortune India • McKesson Supplier of the Year Award - 2019 • India Pharma Leader Award - India Pharma 2020 and India Medical Device 2020 conference organized by FICCI and the Ministry of Chemical
Slide 5: Q2 FY2021 Snapshot
Q2 FY2021 Snapshot Important developments Sales (INR mn, YoY Growth) Commercial India, North America, Mr. Nilesh.D.Gupta • USFDA approval and launch of our 1st inhalation 13,323, (0.7%) Managing Director 13,984, 6% Lupin Limited product, gProAir HFA (Albuterol sulfate) - a key rescue inhaler for ast
Slide 6: Strategic Vision
Strategic Vision Well Diversified Pharma Business Sustain and Evolve our Portfolio Build our Specialty Grow our with a Complex Business and Strong Foundation Generics Focus Novel products Amongst the Top 10 generic Investing heavily in developing high Committed to building a strong companies in the
Slide 7: Q2 FY2021 Financial Results Review
Q2 FY2021 Financial Results Review
Slide 8: P&L Highlights – Q2 FY2021
P&L Highlights – Q2 FY2021 % of QoQ % of % of YoY Amount in INR mn Q2 FY21 Q1 FY21 Q2 FY20 sales growth sales sales growth Net sales 37,818 100.0% 34,686 100.0% 9.0% 38,202 100.0% (1.0%) Other operating income 532 593 620 Total revenue 38,350 35,279 8.7% 38,822 (1.2%) Gross profit 24,001 63.5% 21,80
Slide 9: North America
Q2FY21 North America 37% YoY 2.2% QoQ 14.6% Gaining strong momentum aided by key launches Consolidating our position in the US1 US quarterly sales (US$ mn) #4 #3 #3 #3 212 140 6 184 186 180 120 #4 5 157 28.8% average #5 129 123 121 100 4 109 market share1 80 3 60 79 83 40 65 63 62 2 44 45 51 20 1 0
Slide 10: India
Q2FY21 India 35% YoY 0.7% QoQ 3.6% Consistent Outperformer Leadership across cardiac, diabetes, and respiratory India quarterly Sales (INR bn) IQVIA Q2 FY21 5 Year CAGR % Lupin Rank1 (YoY% growth) MAT MAT 13.4 Therapy Market Lupin 13.0 12.9 13.3 5.7 Sep-15 Sep-20 11.9 Acute 8% 5% 12 15 4.0 Chronic 1
Slide 11: Other Markets: Developed, Emerging, API and Global Institutional
Other Markets • Germany: EUR 8.1 mn sales in Q2 FY21 EU5 • Developed Our 1st biosimilar Nepexto® (bEtanercept) launched in Germany through commercial partner • ARV’s, Inhalation and CNS are the key focus therapeutic segments • 4th largest generics player1 Australia • Q2 FY21 revenues of AU$ 14.4 mn
Slide 12: Manufacturing and R&D – Diverse Global Network
Manufacturing and R&D – Diverse Global Network Global Commercial Presence 100 23 7 Countries where Countries with Countries with OPERATIONS products are sold marketing offices subsidiaries RESEARCH 15 7 Manufacturing Sites R&D Sites ◼ 12 USFDA inspected sites ◼ 436 US ANDAs; 280 approved ◼ 30 bn+ ex
Slide 13: R&D – Higher focus on complex products and FTFs
R&D – Higher focus on complex products and FTFs Invested INR 3.8 bn or 10.2% of sales on R&D in Q2 FY21 at 7 R&D sites globally Optimizing R&D spend US Pipeline 4.5 11.0% 11.5% 12.0% 10.3% 10.2% 436 cumulative filings 4.0 9.1% 10.0% 3.5 3.0 8.0% 2.5 4.2 4.3 6.0% 2.0 3.8 3.4 3.6 156 pending approval
Slide 14: Thank you
Thank you Registered Office Lupin Limited, 3rd Floor, Kalpataru Inspire, Off. Western Expressway Highway Santacruz (East), Mumbai 400 055, India. www.lupin.com www.twitter.com/LupinGlobal www.linkedin.com/company/lupin/ www.facebook.com/LupinWorld/ Phone: +91 22 6640 2323 | Fax: +91 22 6640 2051